Additional studies are needed to define the incidence of this phenomenon in B-cell lymphomas and its correlation with CD19-CAR T cell therapy; however, a previous analysis of B-ALL demonstrated that CD19-CAR T cell therapy may promote immune pressure leading to myeloid switching [70,71]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.